NCT03342547

Brief Summary

The primary objective in this study is to establish a list of host cellular proteins that mediate norovirus infection. Norovirus is one of the most common pathogens attributed to diarrheal diseases from unsafe food. It is also the primary cause of mortality among young children and adults in foodborne infections. Norovirus is not just a foodborne burden. In a recent meta-analysis, norovirus accounts for nearly one-fifth of all causes of (including person-to-person transmission) acute gastroenteritis in both sporadic and outbreak settings and affects all age groups. Undoubtedly, norovirus is of paramount public health concern in both developed and developing countries. Research efforts to better understand norovirus pathobiology will be necessary for targeted intervention. From Middle East respiratory syndrome coronavirus to Zika virus, efforts to identify host factors important for mediating virus infection has always been a research priority. Such information will shed light on potential therapeutic targets in antiviral intervention. Norovirus virus-host interaction studies have been hampered by the lack of a robust cell culture model in the past 20 years. In 2016, norovirus has finally been successfully cultivated in a stem cell-derived three-dimensional human gut-like structure called enteroid or mini-gut. In this study, intestinal stem cells will be isolated from duodenal biopsies collected from participants, followed by differentiation into mini-guts. Genome-wide genetic screening for host essential and restrictive factors will be performed on infected mini-guts by knockout CRISPR and gain-of-function CRISPR SAM, respectively. Shortlisted candidates will undergo preliminary functional validation in cell lines. These data will provide insights into potential therapeutic targets against norovirus infection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 17, 2017

Completed
5 months until next milestone

Study Start

First participant enrolled

April 18, 2018

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

September 20, 2018

Status Verified

September 1, 2018

Enrollment Period

2.7 years

First QC Date

November 9, 2017

Last Update Submit

September 19, 2018

Conditions

Keywords

Norovirus

Outcome Measures

Primary Outcomes (1)

  • Establishment of human intestinal stem cell-derived enteroids

    Viability of enteroids as determined by microscopy

    An average of three months

Study Arms (1)

Intestinal stem cell-derived enteroids

EXPERIMENTAL

Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.

Procedure: Duodenal biopsyProcedure: Saliva

Interventions

Two duodenal biopsy samples will be collected from each participant

Intestinal stem cell-derived enteroids
SalivaPROCEDURE

Saliva (1-2 mL) will be collected from each participant for secretor status testing

Intestinal stem cell-derived enteroids

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 years or above
  • Prospective outpatients undergoing gastrointestinal endoscopy for symptoms of dyspepsia in the Endoscopy Unit of the Prince of Wales Hospital, Shatin, Hong Kong, China
  • Able and willing to provide informed written consent

You may not qualify if:

  • Use of anti-coagulants and/or aspirin that may have increased risk of bleeding
  • History of bleeding diathesis
  • Contraindications for biopsy sampling

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Endoscopy Centre, Prince of Wales Hospital

Hong Kong, China

RECRUITING

Study Officials

  • Chi-Wai Chan, PhD

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chi-Wai Chan, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 9, 2017

First Posted

November 17, 2017

Study Start

April 18, 2018

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

September 20, 2018

Record last verified: 2018-09

Locations